Phase 2 CAR-T Combined With ASCT for High-risk Relapsed/Refractory Large B-cell Lymphoma

NIH has added a new clinical trial registration to ClinicalTrials.gov for a Phase 2 study of axicabtagene ciloleucel combined with ASCT for high-risk relapsed/refractory large B-cell lymphoma. The registration provides the study title, phase, NCT identifier, study type (prospective, single-arm, single-center, open-label), condition (high-risk R/R LBCL), intervention name, and estimated start date of April 20, 2026. No regulatory approval, safety finding, or compliance obligation is associated with this registration entry.

Healthcare providers, clinical investigators, and pharmaceutical companies involved in CAR-T or stem cell transplant programs should treat this as an informational registry entry for awareness purposes only. No compliance action, reporting, or regulatory response is required from this ClinicalTrials.gov listing. Sponsors of competing or complementary trials in this indication space may wish to review the trial protocol for overlap assessment.